Overview
TELO market data
Price History
TELO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.33 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.46 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.89 – $2.15 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $86 · P/B 7.73.
Company News
Telomir Pharmaceuticals Publishes Peer-Reviewed Preclinical Data In Biomedicine & Pharmacotherapy Titled "Telomir-Zn Restores Glucose Homeostasis and Reduces Insulin Resistance in a Diet-Induced Zebrafish Model of Type 2 Diabetes"Benzinga · Jun 15, 2026, 12:10 PM
8-K filing — Telomir Pharmaceuticals, Inc. (TELO)SEC EDGAR · Jun 15, 2026, 12:00 PM
Telomir Pharmaceuticals Appoints Andriy Mushak As Fractional CFO Following Departure Of CFO Alan Weichselbaum, Effective June 6, 2026Benzinga · Jun 8, 2026, 9:10 PM
Telomir Pharma Announces Peer-Reviewed Publication Of Preclinical Data Showing Telomir-Zn Produced Dose-Dependent Survival Improvement Across Multiple Endpoints In Wilson's Disease ModelBenzinga · May 20, 2026, 12:10 PM